ConductScience.org, home

Library / Trial comparisons

Quadrivalent VLP Vaccine vs Placebo: Number of Participants With at Least One New Onset Chronic Diseases (NOCDs)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.01070.008180.0139wilsonClinicalTrials.gov
Risk in group 20.008080.005960.0109wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.00258-0.001210.00644newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.320.8811.98logClinicalTrials.gov
Odds ratio, group 1 over group 21.320.881.99logClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on Quadrivalent VLP Vaccine than on Placebo388from the risk difference intervalthe interval includes no differenceClinicalTrials.gov

Groups 2

Group 2 names the comparator: placebo.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Quadrivalent VLP VaccineParticipants received one IM injection of 0.5 mL of 30 μg/strain of the Quadrivalent VLP Influenza Vaccine on Day 0.545,064OG000ClinicalTrials.gov
Group 2PlaceboParticipants received one IM injection of 0.5 mL of placebo on Day 0.415,072OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Participants With at Least One New Onset Chronic Diseases (NOCDs)ClinicalTrials.gov
Description
All NOCDs that may plausibly have an allergic, autoimmune or inflammatory component were assessed and reported. Plausibility should be interpreted broadly; the only clear exceptions are degenerative conditions such as osteoarthritis, age-related physiologic changes and life-style diseases In this context, most cancers, cardiac conditions and kidney diseases should be reported.
ClinicalTrials.gov
Time frameDay 0 up to ~8 monthsClinicalTrials.gov
PopulationSASClinicalTrials.gov

Trial 8

FieldValueSource
TitleEfficacy, Safety, and Immunogenicity of a Plant-Derived Quadrivalent Virus-Like Particles (VLPs) Influenza Vaccine in AdultsClinicalTrials.gov
NCT numberNCT03301051ClinicalTrials.gov
PhasesPHASE3ClinicalTrials.gov
ConditionsVirus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections, InfluenzaClinicalTrials.gov
InterventionsQuadrivalent VLP Vaccine, PlaceboClinicalTrials.gov
Lead sponsorMedicagoClinicalTrials.gov
Results first posted2023-08-14ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT03301051?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.